Where to from here?, page-47

Hi Woltage,

it’s in everyone’s best interest to diagnose DKD/CKD as early as possible in the disease & to get the patient onto drugs that will prevent progression of the disease. I guess that is why ProMarkerD will be so helpful in detecting the likelihood of developing the disease in the next 4 years & getting the patient onto treatment before the kidney damage starts to show up in screening.

So really, the patient would potentially be on the drug for a lot longer time frame than diagnosing later on. ESKD is treated with dialysis & kidney transplantation, at huge cost to healthcare system & of course detrimental to patients lives.

PIQ were also looking at whether PromarkerD was able to predict cardiovascular disease in diabetes in the Janssen collaboration (for which Janssen have as an indication for Invokana as well as CKD). So again, pointing to a companion diagnostic for Invokana.

Here is an interesting article/interview with a US Specialist on new indications for Invokana. From what I take from this article is that medical advisory bodies will be recommending SGLT2 inhibitors as standard of care along with existing (ARBs etc).

https://www.mdmag.com/medical-news/podcast-canagliflozin-approval-sglt2-inhibitors-bakris

Hopefully we get an update soon .